A Phase 2a Study Evaluating the Safety and Efficacy of RMP-A03 Ocular Suspension in Patients With Pterygium
Latest Information Update: 10 Dec 2024
At a glance
- Drugs RMP-A03 (Primary)
- Indications Pterygium
- Focus Therapeutic Use
- Sponsors Suzhou Raymon Pharmaceuticals
- 10 Dec 2024 Last checked against ClinicalTrials.gov: US National Institutes of Health
- 06 Dec 2024 Status changed from active, no longer recruiting to completed.
- 15 Apr 2024 Planned End Date changed from 1 Feb 2024 to 1 Jul 2024.